[EN] CO-POTENTIATORS FOR THERAPY OF CYSTIC FIBROSIS CAUSED BY MINIMAL FUNCTION CFTR MUTANTS<br/>[FR] CO-POTENTIALISATEURS POUR THÉRAPIE DE LA FIBROSE KYSTIQUE PROVOQUÉE PAR DES MUTANTS CFTR À FONCTION MINIMALE
申请人:UNIV CALIFORNIA
公开号:WO2021041997A1
公开(公告)日:2021-03-04
Provided herein are combination-potentiator ("co-potentiator") therapeutic regimens, which can be used to modulate cystic fibrosis transmembrane conductance regulator (CTFR) mutant proteins. Co-potentiators have potential utility for treatment of many loss-of-function mutations of the CFTR chloride channel (e.g., N1303K).